TPT has developed a unique novel technology for enhancement of bioavailability of Class II and Class IV drugs which are otherwise poorly bioavailable due to solubility and or permeability limitations. The technology is amenable to adapt in any type of oral dosage forms. The technology is simple and easy to scale up. TPT is currently using this platform technology to develop dosage forms for different important drug molecules used in the treatment of hormone replacement therapy, treatment of HIV infection and antifungal treatment.
American Association of Pharmaceutical Scientists(AAPS)
recognizes their members for the impact on their communities, both in the United States and abroad, through humanitarian work which does improve public or global health. Dr. Murthy was bestowed with this premier prestigious award in the year 2022 recognizing his research and community services. Dr. Murthy is the founder of a non-profit research organization, Institute for Drug Delivery and Biomedical Research in India (www.IDBResearch.com)